Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECx Pembrolizumab Registry in Cervical Cancer
2025-522883-34-00Phase 4Authorised
- Sponsor
- University Medical Center Groningen
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab in cervical cancer (mCC) (2 cohorts), sponsored by University Medical Center Groningen. Primary endpoint: Progression-free survival (PFS). Planned start May 2026; status: authorised.
02
Drugs
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on 2025-522883-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522883-34-00.